Skip to main content

Table 1 Patient disposition: long-term analysis

From: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Disposition, n (%)

mBCC

laBCC

All patients

(n = 33)

(n = 71)

(N = 104)

On treatment

1 (3.0)

7 (9.9)

8 (7.7)

Discontinued treatment

32 (97.7)

64 (90.1)

96 (92.3)

Main reason

 AE

5 (15.2)

17 (23.9)

22 (21.2)

 Death

1 (3.0)

2 (2.8)

3 (2.9)

 Lost to follow-up

1 (3.0)

2 (2.8)

3 (2.9)

 Physician decision

3 (9.1)

7 (9.9)

10 (9.8)

 Patient decision

4 (12.1)

23 (32.4)

27 (26.0)

 Disease progression

17 (51.5)

12 (16.9)

29 (27.9)

 Other

1 (3.0)

1 (1.4)

2 (1.9)

  1. AE adverse event, laBCC locally advanced basal cell carcinoma, mBCC metastatic basal cell carcinoma